11:39 uur 06-04-2016

Pharm-Olam International voegt uitvoerend strategisch directeur toe aan afdeling Global Strategic Operations

HOUSTON–(BUSINESS WIRE)– Pharm-Olam International Ltd., een multinationale organisatie voor volledig uitbesteed klinisch onderzoek voor de biofarmacie en medische apparatuur, is verheugd Tricia A. Bland te verwelkomen als nieuw uitvoerend, strategische directeur.

Mevrouw Bland brengt het bedrijf meer dan 20 aan bewezen successen in de sector voor klinisch onderzoek. In deze periode leidde en implementeerde ze ontwikkelingsstrategieën en bestuurde ze met verve internationale teams. Ze is voor Pharm-Olam werkzaam vanuit het kantoor in Research Triangle Park in North Carolina. Bland stelt haar leiderschap van topniveau ter beschikking aan haar personeel, maar ook aan sponsoren. Ze is verantwoordelijk voor strategische relaties en de implementaties van procesverbeteringsprogramma’s, die zijn gericht op grotere efficiëntie en een hogere kwaliteit van data.


Pharm-Olam International Adds Executive Director, Strategic Projects to Its Global Strategic Operations Team

HOUSTON–(BUSINESS WIRE)– Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization to the biopharmaceutical and medical device industries, is pleased to welcome Tricia A. Bland to its management team as the Executive Director, Strategic Projects.

Ms. Bland brings over 20 years of demonstrated success in the clinical research industry, leading and implementing global development strategies and successfully managing global teams. She will be based out of Pharm-Olam’s Research Triangle Park, North Carolina office. Ms. Bland will provide executive-level leadership to both staff and sponsors, strategic relationship management, and implementation of process improvement programs aimed at increasing efficiencies and improving data quality. Prior to coming to Pharm-Olam, Ms. Bland held management roles including Vice President of Corporate Development and Vice President of Proposals and Contracts at several CROs.

“We are thrilled to have Tricia join the Pharm-Olam team,” said Sanjiv Suri, Pharm-Olam’s Chief Executive Officer (USA). Suri added, “We continually look for ways to assist pharmaceutical, biotechnology, and device companies with innovative clinical trial solutions around the world. We know how important our team members are to study success and Tricia’s addition to our team will enable us to offer distinctive ideas to support our client’s unique needs.”

For more information about Pharm-Olam and its global Phase I-IV clinical research solutions, contact info@pharm-olam.com.

About Pharm-Olam International Group

Pharm-Olam International is a multi-national Contract Research Organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com.


Pharm-Olam International
Mark Eberhardt, 713-559-7350

Check out our twitter: @NewsNovumpr